| Literature DB >> 35116724 |
Hui Li1, Yanfa He1, Bin Wang1, Xinliang Song1, Dawei Zhao1, Hang Yu1, Kelei Qi1, Tao Liu1.
Abstract
Pulmonary inflammatory myofibroblastic tumors (IMTs) are rarely reported in adult males. Given the low incidence of IMT and the lack of imaging references and pathological guidance, the misdiagnosis rate of IMT is high. In this article, we describe two cases of IMTs in the lungs. Both patients were adult males with lesions in the right lobe, a history of pulmonary tuberculosis, and a long period of refractory intermittent pulmonary inflammation. Our two male patients both experienced intermittent cough symptoms, but pulmonary IMTs were not suspected for a long time. Both patients were diagnosed with pulmonary tuberculosis before IMT was confirmed and treated with isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) (HRZE) or isoniazid (H), levofloxacin (L), pyrazinamide (Z), and ethambutol (E) (HLZE) for months. In Case 2, we observed multiple subpleural cord signs in the left lung, soft tissue mass shadows at the apex of the right upper lobe, a thickened interlobular interval, and scattered patches and nodules in the upper right lung. These features are novel in the identification of IMTs. Both of the pathological findings revealed a great deal of myofibroblasts, fibroblasts and collagen fibers in the lower right lung lesion, accompanied by a large number of plasma cells and foam cell infiltration, which were consistent with the features of IMT. The two patients displayed exceedingly different symptoms, computed tomography (CT) imaging features, and pathological results from those reported in traditional records. These findings provide novel references that will extend understandings of this rare disease. 2021 Translational Cancer Research. All rights reserved.Entities:
Keywords: Inflammatory myofibroblastic tumor (IMT); case report; inflammatory pseudotumor; lung cancer
Year: 2021 PMID: 35116724 PMCID: PMC8797295 DOI: 10.21037/tcr-21-1683
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Blood indices at several key time points for Case 1
| Time | Indices | Value |
|---|---|---|
| 2020-02-19 | WBC (109) | 10.18 |
| Neutrophils (109) | 6.77 | |
| Lymphocytes (109) | 2.22 | |
| Monocyte (109) | 0.41 | |
| RBC (109) | 4.8 | |
| Hemoglobin (g/L) | 137 | |
| Platelets (109) | 304 | |
| ALT (U/L) | 41 | |
| AST (U/L) | 24 | |
| ALP (U/L) | 93 | |
| TBIL (U/L) | 5.7 | |
| D-dimer value (mg/L) | 0.12 | |
| CYFRA21-1 (ng/mL) | 1.8 | |
| CEA (ng/mL) | 2.38 | |
| SCC (ng/mL) | 2.12 | |
| NSE (ng/mL) | 10.5 | |
| 2020-03-09 | WBC (109) | 9.41 |
| Neutrophils (109) | 6.61 | |
| Lymphocytes (109) | 2.03 | |
| Monocyte (109) | 0.3 | |
| RBC (109) | 4.9 | |
| Hemoglobin (g/L) | 141 | |
| Platelets (109) | 321 | |
| ALT (U/L) | 46 | |
| AST (U/L) | 29 | |
| ALP (U/L) | 114 | |
| TBIL (U/L) | 5.1 | |
| D-dimer value (mg/L) | 0.16 | |
| 2020-03-16 | WBC (109) | 8.91 |
| Neutrophils (109) | 5.76 | |
| Lymphocytes (109) | 2.22 | |
| Monocyte (109) | 0.43 | |
| RBC (109) | 4.19 | |
| Hemoglobin (g/L) | 119 | |
| Platelets (109) | 307 |
WBC, white blood cell; RBC, red blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; CYFRA21-1, cytokeratin 19 fragment; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma; NSE, neuron-specific enolase.
Figure 1Typical CT images of Case 1 on February 13, 2020. (A) The upper lung; (B) the lower lung. CT, computed tomography.
Blood indices at several key time points for Case 2
| Time | Indices | Value |
|---|---|---|
| 2018-04-27 | WBC (109) | 7.14 |
| Neutrophils (109) | 5.33 | |
| Lymphocytes (109) | 1.02 | |
| Monocyte (109) | 0.73 | |
| RBC (109) | 3.94 | |
| Hemoglobin (g/L) | 109 | |
| Platelets (109) | 267 | |
| ALT (U/L) | 10 | |
| AST (U/L) | 14 | |
| ALP (U/L) | 82 | |
| TBIL (U/L) | 7.2 | |
| CYFRA21-1 (ng/mL) | 1.6 | |
| CEA (ng/mL) | <0.2 | |
| AFP (ng/mL) | 1.32 | |
| CA125 (ng/mL) | 12.49 | |
| CA153 (ng/mL) | 10.36 | |
| CA199 (ng/mL) | 5.1 | |
| SCC (ng/mL) | 0.5 | |
| NSE (ng/mL) | 7.34 | |
| 2020-05-16 | WBC (109) | 4.15 |
| Neutrophils (109) | 2.58 | |
| Lymphocytes (109) | 1.21 | |
| Monocyte (109) | 0.28 | |
| RBC (109) | 3.53 | |
| Hemoglobin (g/L) | 96 | |
| Platelets (109) | 209 | |
| ALT (U/L) | 8 | |
| AST (U/L) | 16 | |
| ALP (U/L) | 82 | |
| TBIL (U/L) | 2.8 | |
| 2020-06-05 | WBC (109) | 5.09 |
| Neutrophils (109) | 3.5 | |
| Lymphocytes (109) | 1.22 | |
| Monocyte (109) | 0.32 | |
| RBC (109) | 3.69 | |
| Hemoglobin (g/L) | 99 | |
| Platelets (109) | 244 | |
| ALT (U/L) | 7 | |
| AST (U/L) | 17 | |
| ALP (U/L) | 79 | |
| TBIL (U/L) | 3.8 | |
| 2020-06-23 | WBC (109) | 8.49 |
| Neutrophils (109) | 5.66 | |
| Lymphocytes (109) | 1.62 | |
| Monocyte (109) | 0.55 | |
| RBC (109) | 3.52 | |
| Hemoglobin (g/L) | 97 | |
| Platelets (109) | 440 | |
| ALT (U/L) | 9 | |
| AST (U/L) | 13 | |
| ALP (U/L) | 68 | |
| TBIL (U/L) | 4.3 |
WBC, white blood cell; RBC, red blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; CYFRA21-1, cytokeratin 19 fragment; CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA125, cancer antigen 125; CA153, cancer antigen 153; CA199, cancer antigen 199; SCC, squamous cell carcinoma; NSE, neuron-specific enolase.
Figure 2Typical CT images of Case 2 on June 8, 2018. CT, computed tomography.